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revealing as pulmonary Kaposi sarcoma in
adrenal Cushing’s syndrome
Margarita Bala1*, Cristina L Ronchi1, Josef Pichl2, Vanessa Wild3, Stefan Kircher3, Bruno Allolio1 and Stefanie Hahner1Abstract
Background: Kaposi sarcoma (KS) is a malignant disease most commonly diagnosed in the setting of a human
immunodeficiency virus (HIV) infection and in patients receiving immunosuppressive treatment. Pulmonary KS has
never been reported in association with endogenous Cushing’s syndrome (CS).
Case presentation: A 60-year-old woman presented with symptoms and signs of CS. Adrenal CS was confirmed by
standard biochemical evaluation. Imaging revealed a right adrenal lesion (diameter 3.5 cm) and multiple pulmonary
nodules, suggesting a cortisol-secreting adrenal carcinoma with pulmonary metastases. The patient underwent right
adrenalectomy with a pathohistological diagnosis of an adrenal adenoma. Subsequent thoracoscopic wedge
resection of one lung lesion revealed pulmonary KS with positive immunostaining for human herpes virus 8 (HHV-8).
HIV-serology was negative. Hydrocortisone replacement was initiated for secondary adrenal insufficiency after surgery.
Post-operative follow up imaging showed complete remission of all KS-related pulmonary nodules solely after
resolution of hypercortisolism.
Conclusion: KS may occur in the setting of endogenous CS and may go into remission after cure of hypercortisolism
without further specific treatment.
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Endogenous Cushing’s syndrome (CS) is a rare disorder
with an incidence of ca. 1/100.000 population [1,2]. The
symptoms and signs of CS like truncal obesity, moon face,
diabetes mellitus, hypertension and muscle weakness
result from chronic glucocorticoid excess. Causes of en-
dogenous hypercortisolism include corticotropin-dependent
forms (corticotropic adenoma of the pituitary or ectopic
corticotropin secretion) and corticotropin independent
forms due to adrenal tumors or primary adrenal hyperpla-
sia [1-3]. The diagnosis is based on the clinical presenta-
tion, established biochemical tests (consensus paper) and
imaging techniques.
Kaposi sarcoma (KS) is a vascular, highly malignant
tumor involving blood and lymphatic vessels [4] with an
incidence of ca. 1.2/100.000 (Surveillance Epidemiology* Correspondence: bala_m@ukw.de
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2008–2010). This neoplasm is mostly associated with
human herpesvirus 8 (HHV-8) infection, a virus also
known as Kaposi-sarcoma-associated Herpes virus (KSHV),
which may be transmitted sexually, through blood or sal-
iva, or after organ transplantation [5,6]. A dysregulation of
the immune system is frequently involved in the patho-
genesis of KS [7]. For this reason, KS became more widely
known after the onset of the AIDS epidemic, but it has
been also described among patients that underwent organ
transplantation and subsequent immunosuppressive treat-
ment [5,8]. KS has also been reported after corticosteroid
therapy [9]. According to clinical and pathogenetic fea-
tures, four subtypes of KS are currently distinguished:
1. classic (sporadic or Mediterranean), which mainly
affects elderly people, 2. iatrogenic, which is observed
in immunosuppressed patients usually after transplant-
ation or after treatment for autoimmune disorders, 3. en-
demic, in some African countries and 4. epidemic, being
human-immunodeficiency-virus (HIV) syndrome-related. This is an Open Access article distributed under the terms of the Creative
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the case of epidemic (HIV-related) or iatrogenic KS, treat-
ment primarily aims at immune reconstitution by means
of highly active antiretroviral therapy (HAART) or reduc-
tion of immunosuppressive therapy, respectively [11,12].
We recently experienced the extraordinary case of an
adrenal CS associated with pulmonary KS, which reached
a complete remission after treatment of CS by adrenalec-
tomy. To our knowledge this is the first reported case of
pulmonary KS related to endogenous CS.
Case presentation
A 60-year-old woman was admitted to our endocrine de-
partment with a diagnosis of Cushing’s syndrome (CS)
presumably caused by a cortisol-secreting adrenal carcin-
oma with pulmonary metastases. The patient reported a
progressive course of central obesity, moon-shaped face,
muscle atrophy and weakness, asthenia and emotional dis-
turbance over the last six years. During this period she
had developed arterial hypertension, which was poorly
controlled despite five antihypertensive drugs. Five years
ago abdominal magnetic resonance (MR) imaging had
been performed in the local hospital for further evaluation
of a suspected liver hemangioma, and revealed an inciden-
tal finding of a 2.5 cm lesion in the right adrenal. No
endocrinological evaluation was performed. Three years
before admission she underwent abdominal computed
tomography (CT) imaging for evaluation of recurrent
hypertensive crises. No change of the adrenal tumor size
was found. Screening for pheochromocytoma and primary
hyperaldosteronism was negative. In the weeks before
presentation at our department the patient complained
of polyuria and exertional dyspnoe. The family phys-
ician diagnosed diabetes mellitus, which was treated
with dietary measures. Furthermore, abdominal CT im-
aging was repeated, which showed an increase of the
adrenal tumor size to 3.3 cm. The patient was subse-
quently admitted to the local hospital for further endo-
crinological investigation.Table 1 Laboratory and endocrine baseline and function test
Laboratory tests Preope
Lymphocyte count (*1000/μl) 1.26
Lymphocyte (%) 12.9
Cortisol basal (μg/dl) 27
Cortisol after 1 mg Dexamethason-Suppression-Test (μg/dl) 18
Cortisol after short synacthen-Stimulation-Test (μg/dl) Not ap
24-hour urine cortisol (μg/L) 270
Midnight salivary cortisol (μg/dl) 1.35
ACTH (pg/ml) 8.9
ACTH = adrenocorticotropic hormone. Bold = altered parameters.
* = multiplied by.Laboratory tests performed at the local hospital
showed failure to suppress cortisol levels after 1 mg
dexamethasone and elevated 24-hour urine cortisol se-
cretion. Plasma adrenocorticotropin (ACTH) levels were
suppressed indicating an adrenal origin of the hypercor-
tisolism (Table 1). A pulmonary nodule was suspected in
the abdominal CT imaging and an additional chest CT
revealed multiple bilateral pulmonary nodules which
were not described in a CT imaging of the chest per-
formed 5 years earlier. A fluorodeoxyglucose positron
emission tomography (FDG-PET) was performed for
further evaluation. A high uptake of 18 F-FDG for both
the adrenal lesion and the pulmonary nodules was ob-
served (Figure 1 and Figure 2).
The patient presented in our clinic for further evalu-
ation of the suspected metastatic adrenal carcinoma.
The physical examination revealed skin atrophy with
bruises, buffalo hump, central obesity and facial hirsut-
ism. Laboratory tests confirmed the presence of ACTH-
independent hypercortisolism (Table 1). For histological
verification and for “debulking” purposes to potentially
reduce the cortisol excess, the patient underwent a right
laparoscopic adrenalectomy.
Unexpectedly, the histological report indicated an ad-
renocortical adenoma with no evidence of malignancy.
The tumor size was 3.5 cm and the Weiss score was 0,
compatible with a definitive diagnosis of a benign
cortisol-secreting adrenocortical tumor (Figure 3).
Postoperatively signs of CS gradually receded and la-
boratory testing revealed secondary adrenal insufficiency
(Table 1). The patient received intra- and postoperative
glucocorticoid coverage followed by chronic replacement
therapy for adrenal insufficiency. A thoracoscopic wedge
resection with biopsies of the left upper and lower lobe
was performed. Histopathology showed spindle-shaped
cells with positive immunostaining for CD31, CD34 and
for human herpes virus 8 (HHV-8) (Figure 4), consistent
with a diagnosis of pulmonary Kaposi’s sarcoma. Nei-
ther skin lesions nor involvement of the gastrointestinals of the patient before and after adrenalectomy
rative values Postoperative values Normal range
2.89 1-4.05
30.6 25-40
3.9 5-25
3.5 < 1.8
plicable 10.8 > 18
Not applicable 8-70
0.09 0-0.15
6.9 0-46
Figure 1 Imaging of the right adrenal tumor at initial evaluation. i. CT imaging revealed a 3.3 cm right adrenal tumor (white arrow) ii. High
uptake of 18 F-FDG with standardized uptake value (SUV) of 5.0 for the right adrenal lesion (white arrow).
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colonoscopy were unremarkable. Human immunodefi-
ciency virus (HIV) testing was negative and testing of
the immune status showed normal CD4 cell counts
(1014 cells/mm3; normal range: 410–1590 cells/mm3) as
well as a normal CD4/CD8 ratio (1.18; normal range:
0.8-4.2) eight weeks after adrenalectomy. The differential
white blood cell count revealed relative lymphopenia be-
fore the adrenalectomy which was normalised 8 weeks
after adrenalectomy (Table 1).
Palliative treatment with systemic combination chemo-
therapy was considered after the diagnosis of advanced
KS was established, but was refused by the patient. The
patient experienced significant clinical improvement of
her hypercortisolism-related clinical symptoms such as
normalization of hypertension under antihypertensive
medication, fat redistribution and gradual recovery of
muscular strength. Restaging was performed with chest
and abdominal CT three months (Figure 5) and with
FDG-PET/CT six months after the adrenalectomy and
showed complete disappearance of all KS-induced pul-
monary nodules.
Discussion
We here describe a case of adrenal CS associated with
pulmonary KS with complete remission after successfulFigure 2 Imaging of the bilateral pulmonary nodules at initial evalua
CT imaging iii. High uptake of 18 F-FDG in one pulmonary nodule (white artreatment of CS by unilateral adrenalectomy. It is well
known that cortisol excess causes a state of immunosup-
pression [13,14]. KS occurs in patients with an immuno-
compromised state mainly due to advanced HIV disease
or in transplant patients [4,8]. The etiologic agent of al-
most all forms of KS is HHV-8, but additional immuno-
suppression is necessary for the manifestation of this
malignant disease [5]. Corticosteroids seem to play a role
in the development of KS. Classical KS risk was found to
be strongly and independently associated with oral cor-
ticosteroid use [15]. In addition, KS has also been reported
in association with the immunosuppressive effects of sys-
temic steroids in various clinical conditions (iatrogenic
KS). After withdrawal or reduction of corticosteroids a
partial or complete regression of KS may occur [16-19].
The exact pathophysiological mechanism of this associ-
ation is not yet understood. The increased incidence and
severity of KS in transplant recipients was not found to be
associated with direct cellular effects of corticosteroids on
HHV8 reactivation [20]. Glucocorticoids seem however to
induce KS cell proliferation through the regulation of
transforming growth factor-β [21]. Furthermore, in AIDS-
KS tumor biopsies high expression of glucocorticoid re-
ceptors (GRs) was detected as well as an up-regulation of
GRs by KS-growth-promoting factors like tumor necrosis
factor-α [22].tion. i. and ii. Multiple bilateral pulmonary nodules (white arrows) in
row) (SUV of 3.7), highly suspicious for malignancy.
Figure 3 Paraffin sections with immunohistochemical staining of the cortisol-secreting adrenal lesion. i. H-E staining ii. Negative staining
of Ki67 iii. Positive nuclear staining of SF1.
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ACTH dependent CS which both were associated with
cutaneous KS [23,24]. In the first case a 43-year-old
HIV-negative woman from Turkey developed CS due an
ectopic hypothalamic adrenocorticotropic hormone-
secreting adenoma. The patient developed diffuse skin
lesions on her abdomen, legs, eyelids, and toes, which
were proven to be KS by a skin biopsy. Within one
month after transcranial surgery and cure of CS, all skin
lesions disappeared spontaneously [23]. In the second
case a 54-year-old Hispanic HIV-negative man devel-
oped CS due to a pituitary ACTH-secreting adenoma.
Coincidentally he showed numerous raised, purplish,
non-blanching plaques extended throughout his lower
extremities, which were also proven to be KS by skin bi-
opsy. He underwent repeated transphenoidal surgeries
followed by bilateral adrenalectomy. The patient re-
ceived additional treatment with systemic combination
chemotherapy with liposomal doxorubicin and paclitaxel
resulting in a significant decrease of the KS lesions [24].
In our case the patient had adrenal CS and presented
at a late stage of KS (pulmonary Kaposi) indicating lon-
ger term severe immunosuppression. Clinical symptomsFigure 4 Paraffin sections with immunohistochemical staining of the
cytoplasmic staining of CD31 iii. Positive nuclear staining of human herpesof CS were present for at least 5 years and an incidental
adrenal lesion had already been diagnosed in MR im-
aging 5 years before. CS is associated with immune dys-
regulation and CS patients have been shown to display
impairment in immune regulation, including changes in
both the percentage of specific lymphocyte subsets and
specific lymphocyte functional activities [25]. The pa-
tient presented in our clinic for further evaluation of
suspected metastatic adrenal carcinoma, therefore we
did not initially perform any specific preoperative exam-
ination of the patient’s immune system. After establish-
ment of the diagnosis of Kaposi Sarcoma, specific testing
of the immune status showed normal CD4 cell counts
and normal CD4/CD8 ratio. However, testing had been
performed eight weeks after adrenalectomy and after
resolution of the hypercortisolism. Treatment of CS re-
sulted in a complete remission of KS despite a visceral
manifestation which is usually associated with a poor
prognosis [26]. This demonstrates a key role of cortisol
excess in the pathogenesis and the high relevance of res-
toration of immune function for treatment of KS.
Our case also emphasizes the importance of hormonal
workup in adrenal incidentalomas including screeningleft lobe lung biopsy. i. H-E staining ii. Positive membranous and
virus 8 (HHV-8).
Figure 5 Restaging with CT three months after the adrenalectomy
showed disappearance of all KS-induced pulmonary nodules.
Bala et al. BMC Endocrine Disorders 2014, 14:63 Page 5 of 6
http://www.biomedcentral.com/1472-6823/14/63for cortisol-producing adenoma, hyperaldosteronism and
pheochromocytoma which was delayed and only incom-
pletely performed in our patient.
The combination of cortisol excess with positive FDG-
uptake of both the adrenal tumor and the pulmonary
nodules clearly suggested a cortisol-secreting adrenal
carcinoma with pulmonary metastases. Malignant ad-
renal lesions have a higher standardized uptake value
(SUV) than benign lesions, but in most cases have a
tumor diameter >5 cm [27]. Moreover, a high SUV is oc-
casionally also found in benign hormone secreting aden-
omas [27]. Furthermore, the long standing history of an
adrenal incidentaloma in our patient also pointed to the
possibility of a benign tumor, although some increase in
diameter was documented prior admission. These as-
pects supported the indication for a removal of theTable 2 Clinical types of Kaposi sarcoma (KS)
Type of KS Cutaneous
manifestation
Classic
(sporadic or Mediterranean)
Yes
(often limited to
lower extremity)
Endemic
(African)
Yes
Epidemic AIDS-associated Yes
Latrogenic
(immunosuppression-related)
Yes
Endogenic
(endogenous corticosteroid-excess-related)
Yes
(in the literature)
Endogenic (endogenous corticosteroid-excess-associated) KS represents a potential
In bold is underlined the new type of Kaposi sarcoma.adrenal tumor which otherwise would have remained a
matter of debate in stage IV ACC [28].
Currently, four different types of KS are distinguished,
the classic, endemic, epidemic HIV related and the iatro-
genic type which is related to treatment with immuno-
suppressants. Iatrogenic KS shows similar features as
have been observed in the patients with endogenous CS.
Based on our case and the two earlier reports of cutaneous
KS in ACTH dependent CS, we suggest adding a fifth type
of KS with endogenous corticosteroid-excess as cause of
KS (Table 2) being, however, closely related to the iatro-
genic phenotype. The association of KS with both exogen-
ous and endogenous glucocorticoid excess requires a
concurrent HHV-8 infection. Similar to KS in association
with iatrogenic immunosuppression, which may resolve
completely after reduction or discontinuation of immuno-
therapy, effective treatment of endogenous hypercortiso-
lism may also successfully lead to remission of KS.
Conclusions
Our findings demonstrate that endogenous immunosup-
pression due to Cushing’s syndrome may lead to pulmon-
ary Kaposi sarcoma which may regress after treatment of
hypercortisolism. The data emphasize the key role of
glucocorticoid excess in the pathogenesis of Kaposi Sar-
coma and the high relevance of restoration of immune
function for its treatment. The data further emphasize the
need of careful evaluation of patients with adrenal lesions.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.Visceral
manifestation
Clinical course
No
(uncommon)
Low malignant potential
Yes Indolent, occasionally aggressive progression
Yes Indolent, occasionally aggressive progression.
May regress with HIV treatment
Yes May heal spontaneously with reduction or
discontinuation of immunosuppression.
May be aggressive.
Yes
(in our case)
May regress after treatment of hypercortisolism
new form of Kaposi sarcoma.
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